[go: up one dir, main page]

WO2018209022A3 - Methods of treating neuropsychiatric disorders - Google Patents

Methods of treating neuropsychiatric disorders Download PDF

Info

Publication number
WO2018209022A3
WO2018209022A3 PCT/US2018/031961 US2018031961W WO2018209022A3 WO 2018209022 A3 WO2018209022 A3 WO 2018209022A3 US 2018031961 W US2018031961 W US 2018031961W WO 2018209022 A3 WO2018209022 A3 WO 2018209022A3
Authority
WO
WIPO (PCT)
Prior art keywords
neuropsychiatric disorder
subject
treating
methods
neuropsychiatric disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/031961
Other languages
French (fr)
Other versions
WO2018209022A2 (en
Inventor
Steven A. Goldman
Maiken Nedergaard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Rochester
Original Assignee
University of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Rochester filed Critical University of Rochester
Priority to JP2019561753A priority Critical patent/JP7457505B2/en
Priority to CN201880045819.6A priority patent/CN110913689A/en
Priority to US16/612,529 priority patent/US11690876B2/en
Priority to EP18798072.7A priority patent/EP3621434A4/en
Publication of WO2018209022A2 publication Critical patent/WO2018209022A2/en
Publication of WO2018209022A3 publication Critical patent/WO2018209022A3/en
Anticipated expiration legal-status Critical
Priority to US18/135,543 priority patent/US20230293594A1/en
Priority to JP2024040622A priority patent/JP2024075650A/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present disclosure is directed to a method of treating a neuropsychiatric disorder. This method involves selecting a subject having the neuropsychiatric disorder and administering to the selected subject a preparation of glial progenitor cells at a dosage effective to treat the neuropsychiatric disorder in the subject. Another aspect of the disclosure is directed to a method of treating a neuropsychiatric disorder that includes selecting a subject having the neuropsychiatric disorder and administering, to the selected subject, a potassium (K+) channel activator at a dosage effective to restore normal brain interstitial glial K+ levels in the selected subject and treat the neuropsychiatric disorder is also disclosed.
PCT/US2018/031961 2017-05-10 2018-05-10 Methods of treating neuropsychiatric disorders Ceased WO2018209022A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2019561753A JP7457505B2 (en) 2017-05-10 2018-05-10 How to treat neuropsychiatric disorders
CN201880045819.6A CN110913689A (en) 2017-05-10 2018-05-10 Methods of treating neuropsychiatric disorders
US16/612,529 US11690876B2 (en) 2017-05-10 2018-05-10 Methods of treating neuropsychiatric disorders
EP18798072.7A EP3621434A4 (en) 2017-05-10 2018-05-10 TREATMENT METHODS FOR NEUROPSYCHIATRIC DISORDERS
US18/135,543 US20230293594A1 (en) 2017-05-10 2023-04-17 Methods of treating neuropsychiatric disorders
JP2024040622A JP2024075650A (en) 2017-05-10 2024-03-15 Methods for Treating Neuropsychiatric Disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762504340P 2017-05-10 2017-05-10
US62/504,340 2017-05-10

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/612,529 A-371-Of-International US11690876B2 (en) 2017-05-10 2018-05-10 Methods of treating neuropsychiatric disorders
US18/135,543 Division US20230293594A1 (en) 2017-05-10 2023-04-17 Methods of treating neuropsychiatric disorders

Publications (2)

Publication Number Publication Date
WO2018209022A2 WO2018209022A2 (en) 2018-11-15
WO2018209022A3 true WO2018209022A3 (en) 2018-12-20

Family

ID=64105738

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/031961 Ceased WO2018209022A2 (en) 2017-05-10 2018-05-10 Methods of treating neuropsychiatric disorders

Country Status (5)

Country Link
US (2) US11690876B2 (en)
EP (1) EP3621434A4 (en)
JP (2) JP7457505B2 (en)
CN (1) CN110913689A (en)
WO (1) WO2018209022A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2723382A1 (en) 2008-05-08 2009-11-12 University Of Rochester Treating myelin diseases with optimized cell preparations
US10450546B2 (en) 2013-02-06 2019-10-22 University Of Rochester Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders
US9724432B2 (en) 2015-04-30 2017-08-08 University Of Rochester Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder
WO2018209022A2 (en) 2017-05-10 2018-11-15 University Of Rochester Methods of treating neuropsychiatric disorders
JP2021528445A (en) 2018-06-21 2021-10-21 ユニバーシティー オブ ロチェスター How to treat or prevent the onset of Huntington's disease
KR102237349B1 (en) * 2019-10-23 2021-04-07 한국과학기술연구원 Pharmaceutical composition for the treatment or prevention of nicotine addiction and withdrawal comprising miRNA
JP2023520997A (en) 2020-03-25 2023-05-23 サナ バイオテクノロジー，インコーポレイテッド Hypoimmunogenic nerve cells for the treatment of neurological disorders and conditions
CA3234404A1 (en) * 2021-10-20 2023-04-27 Steven A. Goldman Treatment with genetically modified cells, and genetically modified cells per se, with increased competitive advantage and/or decreased competitive disadvantage
JP2025500876A (en) * 2021-12-14 2025-01-15 トラスティーズ オブ タフツ カレッジ Use of hyperpolarizing agents alone and in combination with other therapeutic agents for the treatment of cancer, including glioblastoma - Patent Application 20070123333

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050169902A1 (en) * 2003-12-15 2005-08-04 Borlongan Cesario V. Compositions and methods for enhancing neuroprotection via administration of stem cells and blood brain barrier permeabilizers
US20060292128A1 (en) * 1999-04-09 2006-12-28 Titan Pharmaceuticals, Inc. Methods of treating schizophrenia
US20160317681A1 (en) * 2015-04-30 2016-11-03 University Of Rochester Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3753357A (en) 1970-12-14 1973-08-21 Ovitron Res Corp Method and apparatus for the preservation of cells and tissues
US4199022A (en) 1978-12-08 1980-04-22 The United States Of America As Represented By The Department Of Energy Method of freezing living cells and tissues with improved subsequent survival
US4559298A (en) 1982-11-23 1985-12-17 American National Red Cross Cryopreservation of biological materials in a non-frozen or vitreous state
US5026365A (en) 1987-04-29 1991-06-25 The University Of Massachusetts Method and apparatus for therapeutically treating immunological disorders and disease states
US5082670A (en) 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5283058A (en) 1990-08-30 1994-02-01 The General Hospital Corporation Methods for inhibiting rejection of transplanted tissue
US6497872B1 (en) 1991-07-08 2002-12-24 Neurospheres Holdings Ltd. Neural transplantation using proliferated multipotent neural stem cells and their progeny
CA2148138C (en) 1992-10-28 2002-01-08 Samuel Weiss Biological factors and neural stem cells
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US6245564B1 (en) 1997-01-23 2001-06-12 Cornell Research Foundation, Inc. Method for separating cells
US6361996B1 (en) 1997-05-07 2002-03-26 University Of Utah Research Foundation Neuroepithelial stem cells and glial-restricted intermediate precursors
US6235527B1 (en) 1997-11-29 2001-05-22 University Of Utah Research Foundation Lineage restricted glial precursors from the central nervous system
US6734015B1 (en) 1997-07-04 2004-05-11 University Of Utah Research Foundation Isolation of lineage-restricted neuronal precursors
US20020012653A1 (en) 1997-12-19 2002-01-31 Kevin Pang Bile duct progenitor cells and methods of use
US6812027B2 (en) 1998-03-25 2004-11-02 Cornell Research Foundation, Inc. Discovery, localization, harvest, and propagation of an FGF2 and BDNF-responsive population of neural and neuronal progenitor cells in the adult human forebrain
US8263402B1 (en) 1998-10-19 2012-09-11 Cornell Research Foundation, Inc. Method for isolating and purifying oligodendrocytes and oligodendrocyte progenitor cells
WO2001046384A2 (en) 1999-12-23 2001-06-28 Cornell Research Foundation, Inc. A method for isolating and purifying multipotential neural progenitor cells and multipotential neural progenitor cells
GB2379447B (en) 2000-05-17 2004-12-29 Geron Corp Neural progenitor cell populations
US6852532B2 (en) 2001-03-21 2005-02-08 University Of Utah Research Foundation Method of isolating human neuroepithelial precursor cells from human fetal tissue
WO2002097069A1 (en) 2001-06-01 2002-12-05 University Of Sydney Purification of lineage-specific cells and uses therefor
WO2003014320A2 (en) 2001-08-10 2003-02-20 Cornell Research Foundation, Inc. Telomerase immortalized human neutral stem cells and phenotypically-restricted progenitor cells
CA2458261A1 (en) 2001-08-30 2003-03-06 Stem Cell Therapeutics Inc. Differentiation of neural stem cells and therapeutic use thereof
US20050214940A1 (en) 2002-01-23 2005-09-29 Rao Mahendra S Pure populations of astrocyte restricted precursor cells and methods for isolation and use thereof
WO2003070171A2 (en) 2002-02-15 2003-08-28 Cornell Research Foundation, Inc. Myelination of congenitally dysmyelinated forebrains using oligodendrocyte progenitor cells
US20040029269A1 (en) 2002-05-07 2004-02-12 Goldman Steven A Promoter-based isolation, purification, expansion, and transplantation of neuronal progenitor cells, oligodendrocyte progenitor cells, or neural stem cells from a population of embryonic stem cells
US7285415B2 (en) 2002-07-11 2007-10-23 The Regents Of The University Of California Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury
JP2004129561A (en) 2002-10-10 2004-04-30 Masahiro Sakanaka Neural precursor cell and method for making the same
KR20060002745A (en) 2003-01-13 2006-01-09 마헨드라 에스 라오 Sustained Expression of Candidate Molecules in Proliferative Stem Cells and Progenitor Cells for Delivery of Therapeutic Products
US8642332B2 (en) 2003-03-07 2014-02-04 Cornell Research Foundation, Inc. Identification and isolation of multipotential neural progenitor cells from the subcortical white matter of the adult human brain
JP4966958B2 (en) 2005-03-14 2012-07-04 ノイロサーチ アクティーゼルスカブ Potassium channel modulators and medical use
CN101115736A (en) * 2005-03-14 2008-01-30 神经研究公司 Potassium channel modulators and their medicinal uses
JP4428296B2 (en) 2005-06-10 2010-03-10 セイコーエプソン株式会社 Display panel module and display device
AU2006325975B2 (en) 2005-12-13 2011-12-08 Kyoto University Nuclear reprogramming factor
WO2008089267A1 (en) 2007-01-16 2008-07-24 University Of Rochester Non-human animals with human-glial chimeric brains
CN101743306A (en) 2007-03-23 2010-06-16 威斯康星校友研究基金会 Somatic cell reprogramming
JP2008307007A (en) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag Human pluripotent stem cell induced from human tissue-originated undifferentiated stem cell after birth
US8227247B2 (en) 2007-12-20 2012-07-24 Wisconsin Alumni Research Foundation Method of generating myelinating oligodendrocytes
DK2282779T3 (en) 2008-04-29 2013-05-27 Pharnext NEW THERAPEUTIC PROCEDURES FOR TREATING ALZHEIMER DISEASE AND RELATED DISORDERS THROUGH A MODULATION OF CELLESTRESS RESPONSE
CA2723382A1 (en) 2008-05-08 2009-11-12 University Of Rochester Treating myelin diseases with optimized cell preparations
GB0813403D0 (en) 2008-07-22 2008-08-27 Lectus Therapeutics Ltd Potassium ion channel modulators & uses thereof
EP2361247A4 (en) * 2008-08-06 2012-08-08 Bionevia Pharmaceuticals Inc Flupirtine hydrochloride maleic acid cocrystal
EP2315829B1 (en) 2008-08-08 2015-02-11 Mayo Foundation For Medical Education And Research Induced pluripotent stem cells
EP2379711B8 (en) 2008-12-23 2017-03-22 BOCO Silicon Valley, Inc. Target populations of oligodendrocyte precursor cells and methods of making and using same
WO2010108126A2 (en) 2009-03-19 2010-09-23 Fate Therapeutics, Inc. Reprogramming compositions and methods of using the same
ES2649396T3 (en) 2009-11-12 2018-01-11 Q Therapeutics, Inc. Methods and compositions to expand, identify, characterize and improve the potency of mammalian glial restricted progenitor cells derived
US20120276070A1 (en) 2009-11-17 2012-11-01 Vitro Diagnositics, Inc. Induced Pluripotent Stem Cells and Related Methods
EP2504317A1 (en) * 2009-11-25 2012-10-03 Abbott Laboratories Potassium channel modulators
WO2011090221A1 (en) 2010-01-22 2011-07-28 Kyoto University Method for improving induced pluripotent stem cell generation efficiency
US8206669B2 (en) 2010-07-27 2012-06-26 Air Products And Chemicals, Inc. Method and apparatus for treating a sour gas
CA2815223A1 (en) 2010-10-26 2012-07-19 Case Western Reserve University Differentiation methods for production of glial cell populations
US8993320B2 (en) 2011-01-12 2015-03-31 Tsuneo KIDO Culture method to obtain and maintain a pure or enriched population of mammalian neural stem cells and/or neural/progenitor cells that are prone to differentiate into oligodendrocyte-lineage cells in vitro
US20130324608A1 (en) * 2011-02-18 2013-12-05 Yuanlong Pan Methods and compositions for treating, reducing or preventing damage to the nervous system of animals
AU2013204200B2 (en) 2012-10-11 2016-10-20 Brandeis University Treatment of amyotrophic lateral sclerosis
US10450546B2 (en) 2013-02-06 2019-10-22 University Of Rochester Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders
US10779519B2 (en) 2014-05-13 2020-09-22 University Of Rochester Human glial chimeric model for drug candidate assessment in human gliotrophic viral infections and progressive multifocal encephalopathy
EP3423564A4 (en) * 2016-03-03 2019-08-21 New York Stem Cell Foundation, Inc. MICROGLIAL CELLS DERIVED FROM PLURIPOTENT STEM CELLS AND METHODS OF PREPARATION AND USE THEREOF
WO2018209022A2 (en) 2017-05-10 2018-11-15 University Of Rochester Methods of treating neuropsychiatric disorders
EP3806861A1 (en) 2018-06-18 2021-04-21 University of Rochester Methods of treating schizophrenia and other neuropsychiatric disorders
JP2021528445A (en) 2018-06-21 2021-10-21 ユニバーシティー オブ ロチェスター How to treat or prevent the onset of Huntington's disease
US20220025379A1 (en) 2018-12-11 2022-01-27 University Of Rochester Methods of treating schizophrenia and other neuropsychiatric disorders
EP3999627A2 (en) 2019-07-18 2022-05-25 University of Rochester Cell-type selective immunoprotection of cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060292128A1 (en) * 1999-04-09 2006-12-28 Titan Pharmaceuticals, Inc. Methods of treating schizophrenia
US20050169902A1 (en) * 2003-12-15 2005-08-04 Borlongan Cesario V. Compositions and methods for enhancing neuroprotection via administration of stem cells and blood brain barrier permeabilizers
US20160317681A1 (en) * 2015-04-30 2016-11-03 University Of Rochester Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder

Also Published As

Publication number Publication date
US20200197445A1 (en) 2020-06-25
EP3621434A2 (en) 2020-03-18
US11690876B2 (en) 2023-07-04
CN110913689A (en) 2020-03-24
JP2024075650A (en) 2024-06-04
US20230293594A1 (en) 2023-09-21
JP2020519599A (en) 2020-07-02
JP7457505B2 (en) 2024-03-28
WO2018209022A2 (en) 2018-11-15
EP3621434A4 (en) 2021-03-31

Similar Documents

Publication Publication Date Title
WO2018209022A3 (en) Methods of treating neuropsychiatric disorders
WO2021026218A3 (en) Treatment of central nervous system disorders
WO2020086726A3 (en) Nerve stimulation for treating migraine and other headache conditions
PH12019502793A1 (en) Aadc polynucleotides for the treatment of parkinson`s disease
MX2020008906A (en) Compounds with ferroptosis inducing activity and methods of their use.
NZ758559A (en) Methods for improving memory and cognition and for treating memory and cognitive disorders
WO2019006005A3 (en) Methods and compositions for treating melanoma
MX2019013279A (en) Methods of treating doose syndrome using fenfluramine.
EP4417252A3 (en) Cannabis based therapeutic and method of use
HK1250238A1 (en) Anti-angptl8 antibodies and uses thereof
PH12020551427A1 (en) Epinephrine spray formulations
MX2018004947A (en) Methods for treating angelman syndrome and related disorders.
MX2017002271A (en) Compositions and methods for treatment of neurological disorders.
MX2020008680A (en) Combination therapy with apilimod and glutamatergic agents.
EP4397372A3 (en) Methods of treating lennox-gastaut syndrome using fenfluramine
MX2016000180A (en) Systems and methods for a tinnitus therapy.
PH12021550176A1 (en) Method for treating epilepsy
EP4345110A3 (en) Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
MX2021010058A (en) Topical rapamycin formulations and their use in treating facial angiofibromas and other skin disorders.
MX2021013354A (en) Methods of treating and/or preventing actinic keratosis.
EP4324454A3 (en) Cross-linking agents and associated methods
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
WO2017190044A8 (en) Methods for detecting and treating pain using brain activity
WO2016161055A3 (en) Methods of treating cancers, autoimmune disorders, and other conditions associated with chronic inflammation
MX2020010302A (en) Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethyl enyl)cyclopent-1-ene-1-carboxylic acid in the treatment of eye disorders.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18798072

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2019561753

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018798072

Country of ref document: EP

Effective date: 20191210

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18798072

Country of ref document: EP

Kind code of ref document: A2